Skip Intro

Dicerna Pharmaceuticals

In August 2013, Deerfield participated in a $60 million Series C financing for Dicerna, a then private company developing novel RNA interference (RNAi)-based therapeutics. Dicerna is a leader in this rapidly emerging field, using its proprietary Dicer Substrate Technology to develop breakthrough therapies for important unmet medical needs.